Casgevy’s approval changed the sickle cell disease landscape. Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, the therapy showed that the disease could be tackled at its genetic root, ...
US drug pricing policy and Congressional Budget Office (CBO) model of the Build Back Better Act examining pharmaceutical R&D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results